Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

DFT383 en participantes pediátricos con cistinosis nefropática (CYStem)

15 de octubre de 2026 actualizado por: Novartis Pharmaceuticals

Un estudio abierto de fase I/II de múltiples centros para evaluar la seguridad, la tolerabilidad y la eficacia de DFT383 en participantes pediátricos con cistinosis nefropática

An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.

The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.

This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.

Descripción general del estudio

Estado

Reclutamiento

Intervención / Tratamiento

Descripción detallada

This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.

The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.

Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.

The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.

Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.

Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

30

Fase

  • Fase 2
  • Fase 1

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

  • Nombre: Novartis Pharmaceuticals

Ubicaciones de estudio

    • Arizona
      • Phoenix, Arizona, Estados Unidos, 85016
        • Reclutamiento
        • Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
        • Contacto:
        • Investigador principal:
          • Shanna White
    • California
      • San Diego, California, Estados Unidos, 92123
        • Reclutamiento
        • University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
        • Contacto:
          • Mieko Pretlow
          • Número de teléfono: Ext 226010 858-966-1700
          • Correo electrónico: mpretlow@rchsd.org
        • Investigador principal:
          • Nadine Benador nbenador@health.ucsd.edu
      • Stanford, California, Estados Unidos, 94305
        • Reclutamiento
        • Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
        • Investigador principal:
          • Alice Bertaina
        • Contacto:
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Reclutamiento
        • Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
        • Investigador principal:
          • Laurence (Larry) Greenbaum
        • Contacto:
          • Laurence (Larry) Greenbaum
          • Número de teléfono: 404-712-6374
          • Correo electrónico: lgreen6@emory.edu
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Reclutamiento
        • Children's Hospital of Philadelphia (Recruiting Cohort 0)
        • Contacto:
          • Melissa Cadnapaphornchai
          • Número de teléfono: 215-590-2449
        • Investigador principal:
          • Melissa Cadnapaphornchai
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • Reclutamiento
        • Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
        • Contacto:
        • Investigador principal:
          • Ewa Elenberg

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

2 años a 5 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Key Inclusion Criteria:

Participants eligible for inclusion in this study must meet all the following criteria:

  1. Informed consent in writing from parent(s) or legal guardian(s) must be provided
  2. 2 to 5 years of age (including 5 years and 364 days old) at Screening
  3. Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
  4. Oral cysteamine therapy for at least 6 months
  5. Historic clinical diagnosis of nephropathic cystinosis
  6. Laboratory evidence of of renal fanconi syndrome (RFS)
  7. Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
  8. Received all age-appropriate vaccinations

Key exclusion Criteria for Cohort 1 and 0

  1. A history of kidney transplantation
  2. A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
  3. History of malignancy
  4. A severe or uncontrolled medical disorder
  5. Major surgery within 90 days

Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:

1. Indomethacin within 2 weeks prior to Screening

Other protocol-defined inclusion/exclusion criteria may apply.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Cohort 1 (DFT383)

Treatment with DFT383

DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy.

Sin intervención: Cohort 0 (SoC)

No study treatment, will continue with standard of care (cysteamine).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Core Phase - Incidence of adverse events (Cohort 1)
Periodo de tiempo: Up to 32 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 32 months
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Periodo de tiempo: 42 days post DFT infusion

Hematological reconstitution by Day 42 post-DFT383 infusion

42 days post DFT infusion
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Periodo de tiempo: Up to 32 months

Proportion of participants with reversal of renal Fanconi syndrome (RFS)

Up to 32 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Core Phase - Number of participants independent from cysteamine
Periodo de tiempo: up to 24 months

Independence from oral and ophthalmic cysteamine

up to 24 months
Core Phase - Health-related quality of life (HRQOL)
Periodo de tiempo: Up to 32 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 32 months
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Periodo de tiempo: Up to 24 months

Time from infusion to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Periodo de tiempo: Up to 24 months

Time from screening to reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Duration of reversal of RFS
Periodo de tiempo: Up to 24 months

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 24 months
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Periodo de tiempo: Up to 27 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 27 months
Core Phase - Change from baseline on urine amino acids
Periodo de tiempo: Up to 27 months

Change from baseline on urine amino acids

Up to 27 months
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Periodo de tiempo: Up to 27 months

Change from baseline on urinary glucose to creatinine ratio

Up to 27 months
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Periodo de tiempo: Up to 27 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 27 months
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Periodo de tiempo: Up to 27 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 27 months
Core Phase - Number of participants with improvement of proximal tubular function
Periodo de tiempo: Up to 27 months

Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization.

Up to 27 months
Core Phase - Corneal cystine crystal content
Periodo de tiempo: Up to 27 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 27 months
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Periodo de tiempo: Up to 27 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 27 months
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Periodo de tiempo: Up to 27 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 27 months
Core Phase - Number of participants with malignancy (Cohort 1)
Periodo de tiempo: Up to 27 months

Number of participants with malignancy

Up to 27 months
Core Phase - Time to hematological reconstitution (Cohort 1)
Periodo de tiempo: Up to 24 months

Time to hematological reconstitution

Up to 24 months
Core Phase - Time to platelet engraftment (Cohort 1)
Periodo de tiempo: Up to 24 months

Time to platelet engraftment

Up to 24 months
Core Phase - Incidence of Adverse Events (Cohort 0)
Periodo de tiempo: up to 24 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

up to 24 months
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Periodo de tiempo: Up to 15 years and 8 months

Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs)

Up to 15 years and 8 months
Extension Phase - Number of participants with malignancy (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Number of participants with malignancy

Up to 15 years and 3 months
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Number of participants with presence/emergence of replication-competent lentivirus

Up to 15 years and 3 months
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Change from baseline on urine protein to creatinine ratio (UPr/CR)

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Change from baseline on urine amino acids

Up to 15 years and 3 months
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Change from baseline on urinary glucose to creatinine ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio

Up to 15 years and 3 months
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Change from baseline on urine retinol-binding protein/creatinine ratio

Up to 15 years and 3 months
Extension Phase - Duration of reversal of RFS (Cohort 1)
Periodo de tiempo: Up to 15 years

Duration of reversal of renal Fanconi syndrome (RFS)

Up to 15 years
Extension Phase - Number of participants with kidney failure (Cohort 1)
Periodo de tiempo: Up to 15 years

Number of participants with kidney failure

Up to 15 years
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Periodo de tiempo: Up to 15 years

Independence from oral and ophthalmic cysteamine

Up to 15 years
Extension Phase - Corneal cystine crystal content (Cohort 1)
Periodo de tiempo: Up to 15 years and 3 months

Corneal crystal content by anterior segment optical coherence tomography (AS-OCT)

Up to 15 years and 3 months
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Periodo de tiempo: Up to 15 years and 8 months

Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development

Up to 15 years and 8 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de junio de 2025

Finalización primaria (Estimado)

28 de mayo de 2031

Finalización del estudio (Estimado)

28 de mayo de 2044

Fechas de registro del estudio

Enviado por primera vez

17 de marzo de 2025

Primero enviado que cumplió con los criterios de control de calidad

27 de marzo de 2025

Publicado por primera vez (Actual)

4 de abril de 2025

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir